Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...

An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due ...

Viking Therapeutics, Inc. (NASDAQ: VKTX) director J. Matthew Singleton executed a sale of company stock valued at more than $715,000, according to a recent SEC filing. The transac ...

Deutsche Bank analyst James Shin has maintained their bullish stance on LLY stock, giving a Buy rating on September 16. James Shin has given ...

Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...

Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...

Shares of Eli Lilly & Co. LLY advanced 1.11% to $915.04 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 and ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 586.36% and ...

Bridgewater Associates, the largest hedge fund in the world, recently sold its sizable stakes in tech giant Apple (AAPL) and ...

Citi reinstated its coverage of Eli Lilly & Co. (NYSE: LLY) with a Buy rating and a target price of $1,060 per share in a ...

Coverage of the current health news ranges from the struggles of Africa with mpox to the forecasted sales of Moderna vaccines. Other highlights include Fulcrum's stock drop due to failed trials, ...

Moderna (NASDAQ: MRNA), a coronavirus vaccine giant, has struggled as that market opportunity continues to shrink. In the most recent quarter, the biotech once again lowered its revenue forecast -- to ...